Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Shares in Open Market
SEC Form 4 Filing
Aprea Therapeutics' CEO, Oren Gilad, recently purchased additional shares of the company's common stock in the open market.
Summary
- Oren Gilad, the President/CEO of Aprea Therapeutics, acquired 150 shares of common stock on October 10, 2024, at a price of $2.54 per share.
- He then acquired 1,000 shares of common stock on October 14, 2024, at a price of $2.59 per share.
- Following these transactions, Gilad directly owns 332,645 shares of Aprea Therapeutics' common stock.
- Gilad also has indirect ownership of 1,200 shares through his daughter and 600 shares through his son.
- He disclaims beneficial ownership of these indirectly held shares.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's stock purchases, which can signal confidence in the company's future.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/10/2024 | Oren Gilad purchased 150 shares of common stock at $2.54 per share. |
| 10/14/2024 | Oren Gilad purchased 1,000 shares of common stock at $2.59 per share. |
| 10/15/2024 | Date of signature by Attorney-in-Fact, John Hamill. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.